

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 1, 2006
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 1, 2006.

2. Welcome

Carmelo Cinqueonce, Executive Vice President of the South Carolina Pharmacy Association, welcomed members and guests.

Dr. LaCroix called the meeting to order and welcomed members, guests, and staff members.

Dr. LaCroix opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

Dr. LaCroix, introduced and welcomed Robert Kerr, South Carolina Medicaid Director, to the P&T meeting. Mr. Kerr thanked the committee and industry representatives for all their efforts in contributing to the success of S. C. Medicaid's Preferred Drug List. Mr. Kerr also informed attendees that the state had announced its intent to join the National Medicaid Pooling Initiative (NMPI). He discussed the fact that it was prudent to join the NMPI due to the impact of Medicare Part D on the Medicaid pharmacy program and further explained that the state's participation in the pooling initiative would be transparent to the Committee. This change affects contracting issues only, therefore, P&T meetings will continue and the Committee will continue to operate as it did prior to the state joining the NMPI.

3. Committee Members Present :

Edward M. Behling, M.D.
Gregory V. Browning, M.D.
Charmaine George, M.D.
Joe Horvath, M.D.
Kelly Jones, Pharm.D.

Jerome E. Kurent, M.D.
Robin K. LaCroix, M.D.
Tan Platt, M.D.
Thomas Phillips, R.Ph.

Deborah J. Tapley, R.Ph.
George E. Vess, Pharm. D.
Harry H. Wright, M.D.

DHHS Staff Present:

Robert M. Kerr, Medicaid Director
 James M. Assey, R.Ph.
 Wanda Metts
 Deirdra Singleton, J.D.
 Susan Bowling
 Byron Roberts, J.D.
 Caroline Sojourner, R.Ph.

Other Representation:

First Health Services. – Mary Roberts, R.Ph.
 Pharmaceutical Industry Representatives

4. Discussion Topics**A. Committee Meeting Minutes, Wednesday, August 2, 2006 .**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Dr. LaCroix instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Ortho-McNeil Janssen Pharmaceuticals	Rolando Veloso, Pharm. D., Scientific Affairs Liaison, Ortho-McNeil Janssen	Aciphex®
Santarus	Amit Agrawal, M.D., Internal Medicine, currently Gastroenterology & Hepatology Fellowship at MUSC	Zegerid®
AstraZeneca	Mark Henderson, Ph.D., Regional Scientific Manager, Astra Zeneca	Nexium®
Novo Nordisk	Soray Servera, M.D., Endocrinologist, Medical Science Director, Novo Nordisk	Levemir®
Pfizer	Barbara Sue Repik, M.D., Internal Medicine, Easley Family Practice and Internal Medicine, Easley, S.C.	Exubera®
Sanofi-Aventis	Michelle Welborn, Pharm.D., Regional Medical Liaison, Sanofi-Aventis	Apidra®

B. Drug Classes for Re-Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Second Generation Sulfonylureas
- Cholesterol Lowering Agents – Fibric Acids
- Glaucoma Therapy – Alpha₂ Adrenergics
- Proton Pump Inhibitors
- Insulins

NO PA REQUIRED “PREFERRED”	PA REQUIRED
<i>Second Generation Sulfonylureas</i>	
GLIMEPIRIDE GLIPIZIDE GLIPIZIDE ER GLYBURIDE GLYBURIDE MICRONIZED	AMARYL® DIABETA® GLUCOTROL® GLUCOTROL XL® GLYNASE® MICRONASE®
<i>Cholesterol Lowering Agents – Fibric Acids</i>	
GEMFIBROZIL LOFIBRA® TRICOR®	ANTARA® LOPID® TRIGLIDE®
<i>Glaucoma Therapy: Alpha₂ Adrenergics</i>	
BRIMONIDINE ALPHAGAN P®	IOPIDINE®
<i>Proton Pump Inhibitors</i>	
NEXIUM® PREVACID® PRILOSEC OTC®	ACIPHEX® OMEPRAZOLE PRILOSEC® PROTONIX® ZEGERID®
<i>Insulins</i>	
HUMALOG 50/50® HUMULIN 50/50® LANTUS® LEVEMIR® Vial NOVOLOG® NOVOLOG MIX 70/30® NOVOLIN N® NOVOLIN R® NOVLIN 70/30®	APIDRA® EXUBERA® HUMALOG 75/25® HUMALOG® HUMULIN N® HUMULIN R® HUMULIN 70/30® LEVEMIR® pen
The P&T Committee recommended that patients established on insulin pen therapy be grandfathered and allowed to receive Levemir® pen.	

The P&T Committee validated previous decisions for the following classes:

Diabetes Therapy:

Alpha-Glucosidase Inhibitors
Biguanides
Biguanide Combination Products
Meglitinides
Thiazolidinediones

Lipotropic Therapy:

Statins and Combination Products
Cholesterol Absorption Inhibitor
Bile Acid Sequestrants
Niacins

Glaucoma Therapy:

Beta Blockers
Carbonic Anhydrase Inhibitors
Prostaglandin Agonists

Anti-Emetics Serotonin Antagonists

Anticholinergics – COPD Therapy

Antibiotics:

Fluoroquinolones
Macrolides/Ketolides

Hepatitis C Therapy:

Pegylated Interferons
Ribavirins

Cholinesterase Inhibitors – Alzheimers' Therapy

Herpes Antivirals

Topical Immunomodulators

Urinary Tract Antispasmodics

Onychomycosis Antifungals

Narcotic Analgesics

5. **Old Business**

The Committee requested updated data regarding S. C. Medicaid savings and expenditures. For the February 2007 meeting, Mary Roberts agreed to prepare a presentation similar to the report presented at the August 2006 P&T Committee meeting.

6. **New Business**

DHHS will evaluate the utilization of insulin pre-filled devices and regular vials. At a future meeting, information will be brought to the Committee regarding these dosage forms.

6. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Diabetes Therapy:

- Alpha-Glucosidase Inhibitors
- Biguanides, Biguanide Combination Products
- Insulins
- Meglitinides
- Sulfonylureas, Second Generation
- Thiazolidinediones

Lipotropic Therapy:

- Statins and Combination Products
- Cholesterol Absorption Inhibitor
- Bile Acid Sequestrants
- Niacins
- Fibric Acids

Glaucoma Therapy:

- Alpha₂ Adrenergics
- Beta Blockers
- Carbonic Anhydrase Inhibitors
- Prostaglandin Agonists

Anti-Emetics Serotonin Antagonists

Anticholinergics – COPD Therapy

Antibiotics:

- Fluoroquinolones
- Macrolides/Ketolides

Hepatitis C Therapy:

- Pegylated Interferons
- Ribavirins

Cholinesterase Inhibitors – Alzheimers' Therapy

Herpes Antivirals

Topical Immunomodulators

Urinary Tract Antispasmodics

Onychomycosis Antifungals

Narcotic Analgesics

Proton Pump Inhibitors

7. **Closing Comments**

The next meeting will be held on Wednesday, February 7, 2007 at 4:00 p.m. at the same location.

8. **Adjournment**

The meeting adjourned at 5:35 p.m.